CompletedPhase 2NCT04827745
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
Studying Mixed phenotype acute leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Maryland, Baltimore
- Principal Investigator
- Vu Duong, MDUniversity of Maryland, Baltimore
- Intervention
- BLINCYTO (Blinatumomab)(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (1)
- Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04827745 on ClinicalTrials.govOther trials for Mixed phenotype acute leukemia
Additional recruiting or active studies for the same condition.